Sign In
Buy PPCB
$1.02
-0.0300 (-2.86%)
At Close: Aug 04, 2026
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
08:45am, Tuesday, 07'th Oct 2025
Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
08:45am, Wednesday, 17'th Sep 2025
MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
09:00am, Tuesday, 02'nd Sep 2025
Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.
Propanc Biopharma Provides Shareholder Update
07:30am, Monday, 25'th Aug 2025
Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
08:30am, Tuesday, 19'th Aug 2025
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
12:25am, Saturday, 16'th Aug 2025
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
11:00pm, Thursday, 14'th Aug 2025
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments fo
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Show with Joel Block, “Your Advantage Play®, In Search of the Ultimate Competitive Advantage” MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or t
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
08:56am, Thursday, 13'th Jul 2023
Reader interest above 93% of published research articles over the past year MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a bi
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
04:00pm, Wednesday, 05'th Jul 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Provides Shareholder Update
11:49pm, Thursday, 22'nd Jun 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Announces Reverse Stock Split
10:53pm, Monday, 22'nd May 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
01:48am, Friday, 17'th Mar 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
09:02am, Wednesday, 26'th Oct 2022
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
